Business
Our proprietary technology platform enables pharmaceutical companies to accelerate and improve the rate of drug discovery and development
Through the development of epigenetic biomarkers, EpiSwitch® can help pharmaceutical companies to:
REDUCE the risk, cost and time to market for therapeutic development programmes
GAIN significant insights into disease mechanisms, to support the personalisation of medicine
PERSONALISE therapeutics to patients, to ensure better clinical outcomes
Robust and validated, award-winning technology
Highly experience Management team, with deep technical and commercial expertise
Extensive IP portfolio, protected by worldwide patents
Leading position within a large and growing biomarker sector, underpinned by strong macro momentum
Expanding pipeline of revenue generating contracts with leading US/ European/ Swiss pharmaceutical companies
Opportunity for significant value enhancement through multiple licensing opportunities on a global basis
Service Offering

Outcomes:
- Reduced trial failure rates
- Reduced time and cost to market
- Early diagnosis
- Tailoring of therapeutics
- Reduced cost and increased efficacy of therapeutics
- Better patient outcomes
Business model and growth strategy
Strategic aim: Leading the industry standard for CCS-based biomarkers
Pilot
1. Continued development of contracts with pharma and research partners
2. Expand own proprietary pilot research
Expand
3. Complete biomarker panel validation
License
4. Leverage IP licensing opportunities
- Multiple applications
- Multiple pathologies